

Schering-Plough Announces A Shareholder Survey
On Director and Executive Pay

Kenilworth, New Jersey, October 24, 2008 -- Schering-Plough today announced that it will undertake a shareholder survey on director and executive pay.

The survey will be mailed to shareholders with the proxy materials for the 2009 Annual Meeting of Shareholders. The survey results will be discussed in the Compensation Discussion and Analysis section of the proxy statement for the 2010 Annual Meeting of Shareholders.

Schering-Plough believes its compensation program allows it to attract and retain a top management team with deep experience in the pharmaceutical industry, and, because pay moves up and down with company performance, motivates the team to provide long-term high performance. This survey will provide shareholders' views of the current program, which will inform future work of the Compensation Committee and the Board.

"This survey is evidence of our commitment to seek and consider shareholder input, as we did in 2006 with the shareholder survey on majority voting for directors," said Pat Russo, Chair of the Nominating and Corporate Governance Committee of the Board.

"We believe it is important to have an attitude of continuous improvement in our governance and compensation practices, even when the actions we take are well beyond the requirements at that time," said CEO Fred Hassan. Schering-Plough has taken many other voluntary steps to enhance governance and compensation since Hassan was named CEO in 2003, including:

Governance Enhancements	Compensation Enhancements
<ul style="list-style-type: none"> • Eliminated classified board 	<ul style="list-style-type: none"> • Moved to double-triggers for equity award vesting in a change-of-control
<ul style="list-style-type: none"> • Eliminated poison pill 	<ul style="list-style-type: none"> • Added strong stock ownership guidelines for management and the board
<ul style="list-style-type: none"> • Committed that any new poison pill would be submitted to shareholders for a vote 	<ul style="list-style-type: none"> • Added performance-based stock options for executives
<ul style="list-style-type: none"> • Eliminated supermajority voting 	<ul style="list-style-type: none"> • Added a two-year holding period on exercise of stock options for executives
<ul style="list-style-type: none"> • Added a majority voting policy for election of directors to the By-Laws 	<ul style="list-style-type: none"> • Eliminated time-based restricted stock for executives
<ul style="list-style-type: none"> • Added a presiding director role and published the duties 	<ul style="list-style-type: none"> • For new executives, eliminated executive life coverage and prior service credit for pensions
<ul style="list-style-type: none"> • Hold non-management executive sessions at each regular board meeting; and also at many meetings of key board committees, including the compensation committee 	<ul style="list-style-type: none"> • Eliminated cash long-term incentives, to increase the percentage of equity in the pay mix
<ul style="list-style-type: none"> • Began a robust shareholder interaction program 	<ul style="list-style-type: none"> • Added performance-based stock units as a long-term incentive
<ul style="list-style-type: none"> • Elected a governance officer and provided both governance and investor relations contact information in the proxy statement 	<ul style="list-style-type: none"> • Compensation Committee retained an independent compensation consultant, Ira Kay of Watson Wyatt, and the Company instituted a tough independence policy about Schering-Plough work with the firm

Rich Koppes, currently at Stanford Law School and formerly General Counsel of the California Public Employees' Retirement System (CalPERS), will provide oversight of the process used to tabulate and report the survey results. He also will serve as the conduit for shareholders wishing to respond to the survey on a confidential basis.